These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518 [TBL] [Abstract][Full Text] [Related]
9. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539 [TBL] [Abstract][Full Text] [Related]
10. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Gervais F; Paquette J; Morissette C; Krzywkowski P; Yu M; Azzi M; Lacombe D; Kong X; Aman A; Laurin J; Szarek WA; Tremblay P Neurobiol Aging; 2007 Apr; 28(4):537-47. PubMed ID: 16675063 [TBL] [Abstract][Full Text] [Related]
11. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. Kocis P; Tolar M; Yu J; Sinko W; Ray S; Blennow K; Fillit H; Hey JA CNS Drugs; 2017 Jun; 31(6):495-509. PubMed ID: 28435985 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Greenberg SM; Rosand J; Schneider AT; Creed Pettigrew L; Gandy SE; Rovner B; Fitzsimmons BF; Smith EE; Edip Gurol M; Schwab K; Laurin J; Garceau D Alzheimer Dis Assoc Disord; 2006; 20(4):269-74. PubMed ID: 17132972 [TBL] [Abstract][Full Text] [Related]
13. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468 [TBL] [Abstract][Full Text] [Related]
15. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123 [TBL] [Abstract][Full Text] [Related]
16. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. Aisen PS CNS Drugs; 2005; 19(12):989-96. PubMed ID: 16332141 [TBL] [Abstract][Full Text] [Related]
17. Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. Agrawal N; Skelton AA Protein J; 2019 Aug; 38(4):425-434. PubMed ID: 31325011 [TBL] [Abstract][Full Text] [Related]